HealthWarehouse.com Reports Full Year 2025 Results

Core Insights - HealthWarehouse.com reported a record year for 2025 with net sales of $49.0 million, reflecting a 46% increase from 2024, driven by an 87% growth in partner services prescription revenues [1][27] - The company achieved a net income of $265,000 and positive cash flow of $1.6 million for the year, indicating a successful operational performance [2][10] Financial Performance - Net sales increased from $33.6 million in 2024 to $49.0 million in 2025, a rise of $15.4 million or 45.8% [6] - Prescription sales reached $46.2 million in 2025, up by $15.3 million or 49.3% compared to 2024, primarily due to growth in partner services [6] - Direct-to-consumer prescription sales declined by 24.3% in 2025, attributed to reduced sales of higher-cost branded medications and increased competition [6] - Over-the-counter net sales increased by 15.9% from $2.2 million in 2024 to $2.5 million in 2025, mainly due to higher marketplace sales [6] Profitability Metrics - Gross profit for 2025 was $17.1 million, a $3.0 million or 21.4% increase from 2024, despite a decrease in gross margin percentage from 42.0% to 35.0% [8] - Selling, general and administrative (SG&A) expenses totaled $16.7 million in 2025, an increase of $2.5 million or 17.7%, but as a percentage of sales, SG&A decreased by 8.2 percentage points to 34.1% [9] - Adjusted EBITDA for 2025 was $1.6 million, up from $1.1 million in 2024, reflecting improved operational efficiency [10] Operational Highlights - The company processed a record number of prescriptions in 2025, contributing to its overall sales growth [2][4] - HealthWarehouse.com continues to invest in proprietary technology to enhance patient experience and operational efficiency [5] - The company anticipates challenges in 2026 due to the end of its authority to dispense high-dollar compounded GLP-1 medications, which may impact sales until new partnerships are established [7]